AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price objective of $5.50 for the company and are predicting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 62 out of 256 based on the ratings given to related companies.
Several equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of AEterna Zentaris from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. ValuEngine upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. Finally, TheStreet lowered shares of AEterna Zentaris from a “c-” rating to a “d” rating in a report on Thursday, June 13th.
NASDAQ:AEZS opened at $2.90 on Friday. The firm has a market cap of $47.68 million, a price-to-earnings ratio of 11.60 and a beta of 1.25. The company has a 50-day moving average price of $2.85. AEterna Zentaris has a 1-year low of $1.29 and a 1-year high of $5.57.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.18). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $4.20 million. AEterna Zentaris had a negative net margin of 666.76% and a negative return on equity of 328.95%. As a group, analysts forecast that AEterna Zentaris will post 1.71 EPS for the current fiscal year.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Recommended Story: What are benefits of a growth and income fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.